The purpose of this research study is to evaluate the effectiveness and safety of
Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a
rare type of cancer that starts in the white blood cells and eventually can result in rashes
or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up
Period. This study will involve physical examinations, visual assessments, laboratory tests,
PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.